World Aids Day Campaign to Shine a Light of Hope on the HIV/AIDS Epidemic in the United States

Bristol-Myers Squibb Company (NYSE: BMY)Bristol-Myers Squibb Company (NYSE: BMY) in collaboration with the National AIDS Fund (NAF) launched the fourth annual "Light to Unite" campaign in support of World AIDS Day. Light to Unite shines a light on the ongoing HIV/AIDS epidemic in the U.S. and encourages individuals to get involved in the struggle against the disease through the sharing of knowledge and experiences, and through donations that benefit grassroots HIV/AIDS organizations throughout the country.

The Catawba Care Coalition, a community-based HIV testing and counseling center in rural South Carolina, is one of the many HIV/AIDS organizations throughout the U.S. that is able to help individuals in need, in part because of donations from last year's Light to Unite campaign.

"Nearly one in four people with HIV in the U.S. do not know they have it," said Anita Case, executive director of Catawba Care Coalition. "Because of Light to Unite, we've been able to significantly increase our outreach to get people tested and counseled, link them to care if infected, and when they're negative, teach them prevention techniques to make sure they stay negative."

"While progress has been made with new treatments and prevention strategies, we still see 40,000 new HIV infections diagnosed every year in the United States. That is 40,000 too many!" said Kandy Ferree, president and CEO, the National AIDS Fund. "Increasingly, those being impacted by HIV/AIDS live in rural areas, far from information and treatment centers, or live in poverty, unable to access information. We have to go to them. Collaborations, like ours with Bristol-Myers Squibb, can help to change the course of this disease in the United States."

In the United States:

  • An estimated one million people are living with HIV/AIDS.
  • One in four new HIV/AIDS infections is in women.
  • African Americans account for 49 percent of all new HIV/AIDS cases despite representing only about 13 percent of the total population.
  • Every 15 minutes one American becomes infected with HIV.
  • The rate of new HIV/AIDS infections has not declined in over 15 years.
  • The South represents a little more than one third of the population, yet now accounts for nearly half of the estimated number of new AIDS cases.

"Through Light to Unite, Bristol-Myers Squibb is encouraging everyone to help us shine a light on the ongoing HIV/AIDS epidemic in the United States and make a difference in the lives of people with this disease," said Anthony Hooper, president, U.S. Pharmaceuticals, Bristol-Myers Squibb Company. "Our collaboration with the National AIDS Fund helps ensure that the communities hardest hit by the HIV/AIDS epidemic receive critical patient services and support."

The focal point of the Light to Unite campaign is the Web site, http://www.lighttounite.org, where each individual who participates in the campaign can "shine a light" by lighting a virtual candle while learning new facts about HIV/AIDS, sharing stories of personal impact, and giving directly to the National AIDS Fund.

To commemorate this year's World AIDS Day and Light to Unite, Bristol- Myers Squibb is making a $250,000 contribution to the National AIDS Fund, which will be distributed through grants to help organizations provide important services to HIV/AIDS patients, such as treatment, care and prevention programs. One hundred percent of the contribution will be distributed to grant recipients.

The National AIDS Fund provides grants through a network of more than 400 grassroots HIV/AIDS organizations around the country. This approach gives grassroots HIV/AIDS organizations access to needed funding, to offer support services that best meet the needs of their local communities.

About Bristol-Myers Squibb
Bristol-Myers Squibb is a global pharmaceutical and related health care products company whose mission is to extend and enhance human life. Visit Bristol-Myers Squibb at http://www.bms.com.

About the National AIDS Fund
The National AIDS Fund's mission is to reduce the incidence and impact of HIV/AIDS by promoting leadership and generating resources for effective community responses to the epidemic. Through an expanding network of Community Partnerships, the National AIDS Fund promotes collaborative local planning and provides strategic grants and technical support to nearly 400 direct service organizations annually. Since 1988, together with its Community Partnerships, the National AIDS Fund has invested over $142 million to combat the AIDS epidemic in the United States. For more information about the National AIDS Fund, please visit http://www.aidsfund.org.

Most Popular Now

FDA grants Breakthrough Therapy Designation to Pfi…

Pfizer Inc. (NYSE:PFE) today announced that its investigational Group B Streptococcus (GBS) vaccine candidate, GBS6 or PF-06760805, received Breakthrough Therapy Designat...

Novartis invests in early technical development ca…

Novartis today announced it is investing in next-generation biotherapeutics with the creation of a fully integrated, dedicated USD 300m scientific environment that will b...

Malaria booster vaccine shows durable high efficac…

Researchers from the University of Oxford and their partners have today reported new findings from their Phase 2b trial following the administration of a booster dose of ...

Research reveals widespread use of ineffective COV…

Monoclonal antibodies are laboratory-designed treatments tailor-made to fight specific infections. In early 2021, the U.S. Food & Drug Administration issued emergency use...

Strict COVID lockdowns in France improved cardiova…

A new paper in European Heart Journal - Digital Health, published by Oxford University Press, indicates that social-distancing measures like total lockdown have a measura...

Pfizer and BioNTech receive positive CHMP opinion …

Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) announced a 30-µg booster dose of their Omicron BA.4/BA.5 bivalent-adapted COVID-19 vaccine (COMIRNATY® Original/Om...

U.S. clinical trial evaluating antiviral for monke…

A Phase 3 clinical trial evaluating the antiviral tecovirimat, also known as TPOXX, is now enrolling adults and children with monkeypox infection in the United States. St...

Stem cell-gene therapy shows promise in ALS safety…

Cedars-Sinai investigators have developed an investigational therapy using support cells and a protective protein that can be delivered past the blood-brain barrier. This...

Drug turns cancer gene into "eat me" fla…

Tumor cells are notoriously good at evading the human immune system; they put up physical walls, wear disguises and handcuff the immune system with molecular tricks. Now...

Mucosal antibodies in the airways protect against …

High levels of mucosal antibodies in the airways reduce the risk of being infected by omicron, but many do not receive detectable antibodies in the airways despite three ...

WHO strongly advises against antibody treatments f…

The antibody drugs sotrovimab and casirivimab-imdevimab are not recommended for patients with COVID-19, says a WHO Guideline Development Group of international experts in...

WHO grants prequalification to GSK's Mosquirix - t…

GSK plc (LSE/NYSE: GSK) announced that the World Health Organization (WHO) has awarded prequalification to Mosquirix (also known as RTS,S/AS01), GSK's groundbreaking mala...